Comparison of Three Different Chemotherapy Regimens Containing Epirubicin in Hormone-Refractory Prostate Cancer Patients

@inproceedings{Ersoy2008ComparisonOT,
  title={Comparison of Three Different Chemotherapy Regimens Containing Epirubicin in Hormone-Refractory Prostate Cancer Patients},
  author={Hamit Ersoy and Orhan Gazi Yiğitbaşı and Levent Sağnak and Hikmet Topaloglu and Ahmet Namik Kiper},
  booktitle={TheScientificWorldJournal},
  year={2008}
}
We compared three different chemotherapy regimens containing epirubicin in hormone-refractory prostate cancer (HRPC) patients. Sixty-nine patients with HRPC were randomized into three groups. The first group (22 patients) received 30 mg/m2/week i.v. epirubicin for 8 weeks. The second group (24 patients) received 30 mg/m2/week i.v. epirubicin for 8 weeks followed by monthly maintenance therapy for 4-6 months. The third group (23 patients) received oral estramustine phosphate (EMP) at a dose of… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 26 REFERENCES

Weekly chemotherapy in advanced prostatic cancer.

  • British Journal of Cancer
  • 1993
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

a meta-analysis of individual patient data

K. Fizazi, A. LeMaritre, +8 authors survival of patients with castration-refractory prostate cancer
  • Lancet Oncol. 8(11), 994–1000. This article should be cited as follows: Ersoy, H., Yigitbası, O., Sagnak, L., Topaloglu, H., and Kiper, A.
  • 2008
VIEW 1 EXCERPT

based on extent of disease on initial bone scan

S. Bracarda, M. Tonato, +5 authors M. Porena
  • 2000

Phase I trial of docetaxel with estramustine in androgenindependent prostate cancer

D. P. Petrylak, R. B. Macartur, J O'Connor
  • J. Clin. Oncol
  • 1999
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…